ZRG Partners Life Sciences Hiring Index Shows Modest Gains in 4th Quarter
ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index
ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index. Q4 reflects an overall gain in hiring, with Pharma activity over the long term reaching an all-time index high. Meanwhile R&D hiring took a hit dropping 15% from the previous quarter. The Asia Pacific Region saw significant hiring in Q4, more than 25%, with most being attributed to the Sales and Marketing function.
ZRG Managing Director David Fortier commented, “The results of this latest index correlate with the broader economy – inconsistencies across regions, sectors, and functions along with the continuation of a longer term trend of slow, steady, but uneven growth. The positive to take from these numbers is some robust hiring in selected functions within pharmaceuticals and a return of hiring in the commercial function indicating expectations of growth for some companies.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
